List of Excipients in Branded Drug DICLOFENAC SODIUM/MISOPROSTOL

Generic Drugs Containing DICLOFENAC SODIUM/MISOPROSTOL

Company	Ingredient	NDC	Excipient
Micro Labs Limited	diclofenac sodium/misoprostol	42571-133	CELLULOSE, MICROCRYSTALLINE
Micro Labs Limited	diclofenac sodium/misoprostol	42571-133	CROSPOVIDONE
Micro Labs Limited	diclofenac sodium/misoprostol	42571-133	HYDROGENATED CASTOR OIL
Micro Labs Limited	diclofenac sodium/misoprostol	42571-133	HYPROMELLOSES

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM/MISOPROSTOL?

# Of NDCs	Excipient
4	CELLULOSE, MICROCRYSTALLINE
4	CROSPOVIDONE
4	HYDROGENATED CASTOR OIL
1	HYDROXYPROPYL METHYLCELLULOSE

Diclofenac Sodium/Misoprostol Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Diclofenac sodium/misoprostol is an established fixed-dose combination designed to provide NSAID analgesia while reducing NSAID-induced gastric ulcer risk. The principal commercial opportunity is a lower-cost, technically robust delayed-release tablet that preserves misoprostol potency, controls diclofenac release, and meets bioequivalence requirements. The formulation is mature, but manufacturing complexity, moisture sensitivity, pregnancy-related labeling restrictions, and limited market growth constrain returns.

What is the commercial role of diclofenac sodium/misoprostol?

Diclofenac sodium/misoprostol combines:

• Diclofenac sodium, a nonsteroidal anti-inflammatory drug.
• Misoprostol, a prostaglandin E1 analog used to reduce the risk of NSAID-induced gastric and duodenal ulcers.

The reference product is Arthrotec, marketed in the United States as delayed-release tablets containing either:

Strength	Diclofenac sodium	Misoprostol
Arthrotec 50	50 mg	200 mcg
Arthrotec 75	75 mg	200 mcg

The product is intended for patients who require diclofenac and have a meaningful risk of NSAID-induced ulceration. Misoprostol does not eliminate gastrointestinal, cardiovascular, renal, or other NSAID-related risks. The labeling carries a boxed warning because misoprostol can cause uterine contractions, abortion, premature birth, and birth defects. It is contraindicated in pregnancy for prevention of NSAID-induced ulcers unless used under the conditions specified in the labeling.[1]

The product’s commercial value comes from combining two prescriptions into one dosage unit. Its main disadvantages are diarrhea, abdominal cramping, pregnancy restrictions, and the possibility that patients who do not require gastroprotection will prefer low-cost diclofenac alone.

What excipients are used in diclofenac sodium/misoprostol tablets?

The reference formulation uses a multipart excipient system rather than a simple direct-compression blend. The inactive ingredients reported for Arthrotec include common tablet fillers, binders, disintegrants, lubricants, coating materials, and processing aids. The exact composition can vary by strength and manufacturing site.[1,2]

Key excipient functions include:

Excipient function	Candidate materials	Formulation purpose
Diluent	Lactose, microcrystalline cellulose	Tablet mass, compressibility, content uniformity
Binder	Povidone, hydroxypropyl cellulose or related polymers	Granule strength and mechanical integrity
Disintegrant	Croscarmellose sodium, crospovidone	Tablet breakup after the intended release phase
Glidant	Colloidal silicon dioxide	Powder flow and dose uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Film coating	Hypromellose, talc, titanium dioxide, plasticizer	Protection, appearance, swallowability
Enteric coating	Methacrylic acid copolymers or equivalent polymers	Delayed diclofenac release
Barrier or seal coating	Hypromellose, polyvinyl alcohol, or similar polymer	Separation of incompatible layers and moisture control
Plasticizer	Triethyl citrate or polyethylene glycol	Film flexibility and reduced coating defects

The commercial reference product has historically been described as a dual-release or layered system in which misoprostol is made available rapidly while diclofenac is protected from gastric release. A generic developer should treat the release architecture, not only the ingredient list, as the core technical challenge.

Why is excipient selection technically difficult?

Diclofenac sodium and misoprostol have different formulation requirements. Diclofenac requires delayed release to reduce gastric exposure and to reproduce the reference product’s dissolution profile. Misoprostol requires chemical stability and reliable low-dose distribution at a 200-microgram dose.

The formulation must control:

1. Misoprostol degradation during granulation, drying, coating, and storage.
2. Migration of misoprostol into adjacent layers or coating materials.
3. Diclofenac release in acidic media.
4. Rapid diclofenac release after transition to intestinal pH.
5. Uniformity of misoprostol content across the batch.
6. Moisture ingress through the tablet film and packaging.
7. Mechanical damage to enteric-coated particles or layers during compression.

High-moisture excipients, aqueous processing, elevated drying temperatures, and prolonged exposure to alkaline or reactive surfaces can increase development risk. A low-water-activity process, controlled-temperature manufacturing, rapid blending, and high-barrier packaging are likely to be more important than selecting a novel excipient.

What excipient strategy is most commercially attractive?

The strongest generic strategy is a conventional excipient system with a differentiated process-control package. Regulatory authorities generally prefer well-characterized compendial excipients with established oral safety profiles.

Recommended formulation architecture

A practical development platform would use:

• Microcrystalline cellulose and lactose or an equivalent diluent system.
• Povidone or a comparable binder at the lowest level that provides adequate granule strength.
• Crospovidone or croscarmellose sodium for controlled disintegration.
• Magnesium stearate with tightly controlled mixing time.
• A polymeric enteric coating based on a methacrylic acid copolymer.
• A moisture-barrier overcoat.
• High-barrier blister packaging, preferably aluminum-aluminum, for the commercial presentation.

The formulation should avoid unnecessary excipient novelty. Novelty can create additional regulatory questions without providing commercial protection. A developer can obtain meaningful differentiation through:

• Lower moisture uptake.
• Improved tablet hardness without delayed disintegration.
• Reduced misoprostol degradation.
• Better dissolution similarity to Arthrotec.
• Smaller tablet size.
• Lower coating weight.
• Improved stability in warm and humid markets.
• A manufacturing process that reduces solvent, drying, or coating time.

Which excipient risks should developers prioritize?

Misoprostol content uniformity is a high-priority risk because the dose is small relative to the total tablet mass. The active must be distributed through a process that avoids segregation and minimizes localized concentration.

Moisture is a second major risk. It can affect both misoprostol stability and enteric-coating performance. Water activity, residual solvent, packaging permeability, and accelerated stability data should be evaluated together rather than as separate development variables.

Lubrication is another risk. Excess magnesium stearate or excessive blending can reduce tablet wettability and alter dissolution. Enteric-coated particles may also be damaged by compression if the formulation does not provide sufficient cushioning.

What patents protect diclofenac sodium/misoprostol?

The principal product and formulation patents covering the original Arthrotec technology are old and have expired in major markets, including the United States. The historic patent estate included claims directed to:

• Diclofenac and misoprostol combinations.
• Oral dosage forms containing the two active ingredients.
• Differential or delayed release of diclofenac.
• Misoprostol stabilization.
• Layered or coated tablet structures.
• Use of misoprostol to reduce NSAID-induced gastrointestinal injury.

The original patent estate no longer provides a durable barrier to conventional generic development. Current commercial protection is more likely to arise from process know-how, regulatory exclusivity in a particular jurisdiction, manufacturing scale, trademarks, supply agreements, or later patents on modified formulations.

Protection category	Current strategic relevance
Original combination patents	Low in the United States and other mature markets because of expiration
Original formulation patents	Generally expired or near-irrelevant for ordinary generic entry
Orange Book-listed patents	Must be checked against the current FDA listing for the specific NDA
New formulation patents	Potentially relevant if they claim a distinct release or stabilization system
Method-of-use patents	Limited value where the use is already established and label scope is narrow
Process patents	Potentially valuable if they cover a difficult stability or coating process
Trade secrets	Important for low-level misoprostol blending, moisture control, and coating parameters

What is the FDA regulatory and Orange Book status?

Diclofenac sodium/misoprostol is regulated as a small-molecule drug, not a biologic. A generic applicant would ordinarily pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, provided the product can meet the relevant reference-product and bioequivalence requirements.[3]

The regulatory priorities are:

• Same active ingredients and strengths.
• Same dosage form and route of administration.
• Comparable delayed-release behavior.
• Bioequivalence to the reference listed drug.
• Adequate control of misoprostol degradation products.
• Stability through the proposed shelf life.
• Appropriate pregnancy contraindication and risk labeling.
• Demonstration that inactive ingredients are suitable for the intended use.

The Orange Book status depends on the specific reference listing and current FDA records. The original Arthrotec patent barriers are not the principal obstacle to modern entry. The more significant issue is whether a proposed generic can reproduce the reference product’s performance with a commercially scalable process.[4]

Does diclofenac sodium/misoprostol have biologic or biosimilar risk?

No. Diclofenac sodium/misoprostol is a conventional small-molecule combination. Biosimilar litigation, interchangeable-biologic substitution, and biologic patent dance procedures do not apply.

The relevant competitive risks are:

• ANDA filings.
• Paragraph IV patent challenges, if an unexpired listed patent exists.
• Paragraph III certifications for later-expiring patents.
• Authorized generic competition.
• Nonfixed co-prescription of diclofenac and misoprostol.
• Other NSAID and gastroprotection combinations.

When does diclofenac sodium/misoprostol lose exclusivity?

The original product’s meaningful United States exclusivity has already expired. The combination has been commercially exposed to generic competition for years, subject to the availability of approved generic products and local market conditions.

There is no current business case based on preservation of original patent exclusivity. A new entrant would need to compete through:

• Lower cost of goods.
• Reliable supply.
• Government and institutional tenders.
• Geographic expansion.
• A smaller or more patient-friendly tablet.
• Improved packaging for hot and humid climates.
• A differentiated formulation supported by new intellectual property.

Any current Paragraph IV opportunity would depend on a newly listed, unexpired patent covering a specific formulation, manufacturing process, or use. A Paragraph IV challenge to an expired historical patent would have no commercial value.

What formulations are protected by later patents?

Later patents may remain relevant where they claim a formulation that differs materially from the original product. Potential claim areas include:

• Stabilized misoprostol solid dispersions.
• Multiparticulate systems with separate diclofenac and misoprostol release profiles.
• Novel enteric polymers or coating sequences.
• Moisture-resistant tablets.
• Controlled-release diclofenac with immediate-release misoprostol.
• Alternative strengths or dosing schedules.
• Abuse-deterrent or pediatric-restricted presentations, although pediatric use is commercially limited.
• Combination products that incorporate a proton-pump inhibitor or another gastroprotective agent.

A formulation patent is commercially meaningful only if the protected feature is necessary to achieve the target dissolution, stability, or bioequivalence profile. Broad claims directed merely to the presence of diclofenac and misoprostol are less likely to provide durable protection than claims tied to a defined architecture or process.

What generic launch scenarios exist?

Scenario 1: Conventional delayed-release generic

This is the most direct opportunity. The applicant uses standard excipients, an enteric-coated diclofenac component, and a misoprostol-containing layer or granule. The product competes on price and supply reliability.

Advantages: Lowest regulatory novelty and manufacturing risk.
Risks: Price erosion and limited differentiation.

Scenario 2: High-stability tropical-market product

The developer optimizes water activity, coating integrity, and packaging for markets with high temperature and humidity.

Advantages: Potential access to underpenetrated markets and institutional tenders.
Risks: Lower pricing and country-specific registration requirements.

Scenario 3: Smaller-tablet or lower-burden product

A smaller tablet or optimized coating system improves swallowing and adherence.

Advantages: Differentiation without changing the active ingredients.
Risks: Any change in geometry or coating can affect dissolution and bioequivalence.

Scenario 4: Reformulated 505(b)(2) product

A sponsor could pursue a distinct dosage form, strength, release profile, or packaging concept under a 505(b)(2) pathway if the product does not qualify as a conventional generic.

Advantages: Potential labeling, formulation, or market differentiation.
Risks: Higher clinical, regulatory, and patent costs; weak reimbursement leverage.

How strong is the patent estate for a new entrant?

The legacy patent estate is weak as a barrier to a conventional generic. A new entrant’s defensibility would come from a narrow, technically necessary improvement.

Asset	Defensive value
Standard excipient composition	Low
Conventional enteric coating	Low
Specific moisture-control process	Moderate
Stabilized misoprostol formulation	Moderate to high
Distinct multiparticulate release architecture	Moderate to high
New indication without differentiated clinical value	Low
Manufacturing trade secrets	Moderate
Brand and supply reliability	Moderate

The best intellectual-property strategy is a layered portfolio covering composition, process, analytical methods, and packaging. The claims should focus on measurable technical outcomes, such as misoprostol impurity limits, water activity, dissolution windows, or stability after defined storage conditions.

Which companies are competing in the market?

Pfizer is associated with the original Arthrotec brand in the United States. Competition includes generic manufacturers and local pharmaceutical companies that market diclofenac/misoprostol combinations under regional brand names. Market participation varies substantially by country because diclofenac is widely available as a standalone product and misoprostol is often prescribed separately.

The principal competitive products are:

• Generic diclofenac sodium.
• Diclofenac plus a proton-pump inhibitor.
• Diclofenac plus misoprostol.
• Other NSAID/gastroprotection combinations.
• Non-NSAID analgesics for patients with gastrointestinal or cardiovascular risk.

The combination is strongest where prescribers value one-pill adherence and where gastroprotection is routinely integrated into NSAID treatment. It is weaker where generic diclofenac is inexpensive and physicians prescribe gastroprotection separately.

What licensing and partnership opportunities exist?

Licensing value is more likely in formulation technology than in the old active-ingredient combination. Attractive assets include:

• A stable misoprostol granulation platform.
• A scalable low-moisture coating process.
• A compact delayed-release tablet.
• A high-barrier packaging system with long shelf life.
• Regional registration dossiers.
• Established tender access in emerging markets.
• Contract manufacturing capacity for low-dose prostaglandin products.

A commercial partner should evaluate whether the formulation is genuinely differentiated from a standard generic. A license based only on the historical Arthrotec concept is unlikely to justify a substantial upfront payment.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barriers are process control and quality consistency. Misoprostol’s low dose creates a content-uniformity challenge. Diclofenac’s delayed-release requirements create a coating and dissolution challenge. The combination creates an interface problem between these two systems.

Critical manufacturing controls include:

• Controlled humidity during blending and compression.
• Low-shear handling of coated particles.
• Short, validated lubrication time.
• Tight coating-weight gain limits.
• In-process checks for acid-stage resistance.
• Intestinal-stage dissolution testing.
• Stability-indicating assays for misoprostol and degradation products.
• High-barrier primary packaging.
• Segregation control during tableting and bulk handling.

The most defensible know-how may remain outside published patents. Process parameters, order of addition, granulation endpoint, drying profile, coating suspension properties, and packaging configuration can materially affect commercial performance.

What is the revenue exposure and market outlook?

Revenue exposure is limited for an undifferentiated product because the market is mature and exposed to generic price competition. A conventional generic can still generate value where:

• The reference product has limited supply.
• Few approved competitors serve a particular country.
• Hospitals or public payers purchase through tenders.
• Local production receives procurement preference.
• Patients require a fixed combination rather than separate prescriptions.
• The product is available in both 50/200 and 75/200 strengths.

The largest commercial risk is substitution with diclofenac plus a proton-pump inhibitor. That alternative may offer broader prescribing familiarity, even though it does not reproduce the pharmacologic action or dosing convenience of misoprostol.

Key Takeaways

• Diclofenac sodium/misoprostol is a mature small-molecule combination with expired legacy exclusivity in major markets.
• The formulation challenge is the integration of low-dose misoprostol stability with delayed-release diclofenac performance.
• Standard compendial excipients are commercially preferable to novel excipients.
• Moisture control, content uniformity, enteric coating integrity, and high-barrier packaging are the critical development priorities.
• The original patent estate is a weak barrier to conventional generic entry.
• New patents should target stabilization, release architecture, manufacturing processes, or packaging.
• There is no biosimilar pathway or biologic patent risk.
• The strongest commercial opportunities are reliable low-cost generics, tropical-climate products, regional tenders, and technically differentiated high-stability formulations.
• Commercial returns are constrained by low-cost diclofenac monotherapy, separate gastroprotection, misoprostol tolerability, and pregnancy-related restrictions.

FAQs

Can diclofenac sodium/misoprostol be formulated as a simple immediate-release tablet?

A simple immediate-release tablet would not reproduce the reference product’s delayed-release diclofenac behavior and would face substantial bioequivalence and tolerability risks. A successful generic requires a release-control strategy for diclofenac.

Is misoprostol stability more important than diclofenac dissolution?

Both are critical, but misoprostol stability is often the more difficult development variable because the dose is low and the active is sensitive to processing and moisture. Diclofenac dissolution remains essential for regulatory approval.

Is an aluminum-aluminum blister necessary?

It is not universally mandatory, but high-barrier packaging is commercially attractive because it reduces moisture ingress and supports shelf-life control. The packaging choice should be justified by stability data and market conditions.

Can a new excipient create patent protection for the combination?

A new excipient alone rarely creates strong commercial protection. Patent value is higher when the excipient produces a defined technical result, such as improved misoprostol stability, a specific dissolution profile, or enhanced moisture resistance.

Does diclofenac sodium/misoprostol have a viable pediatric market?

The pediatric opportunity is limited. Misoprostol’s reproductive toxicity, NSAID safety considerations, and the lack of a broad pediatric gastroprotection market restrict the value of pediatric development.

References

1. U.S. Food and Drug Administration. (2023). Arthrotec-50 and Arthrotec-75 prescribing information.
2. National Library of Medicine. (2024). Arthrotec-50 and Arthrotec-75: DailyMed drug label.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process for generic drugs.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. United States Pharmacopeia. (2024). USP-NF general chapters for dosage-form performance, dissolution, and content uniformity.